Financial Instruments	12 Months Ended
Dec. 31, 2021
Financial Instruments [Abstract]
Financial Instruments	5. Financial Instruments A summary of financial instruments measured at fair value is as follows (in thousands): December 31, 2021Level 1 Level 2 Level 3 TotalCash equivalents: Money market funds$ 10,015 -- -- $ 10,015Total assets$ 10,015 $ -- $ -- $ 10,015 Long-term liabilities: Contingent consideration -- -- (49,400) (49,400)Total liabilities $ -- $ -- $ (49,400) $ (49,400) December 31, 2020Level 1 Level 2 Level 3 TotalCash equivalents: Money market funds$ 11,484 -- -- $ 11,484Restricted securities: Money market funds 546 -- -- 546Endospan loan -- -- 409 409Total assets$ 12,030 $ -- $ 409 $ 12,439 Current liabilities: Contingent consideration -- -- (16,430) (16,430) Long-term liabilities: Contingent consideration -- -- (43,500) (43,500)Total liabilities$ -- $ -- $ (59,930) $ (59,930) We used prices quoted from our investment advisors to determine the Level 1 valuation of our investments in money market funds. We recorded the Endospan Loan, classified as Level 3, as a result of an agreement with Endospan in September 2019. The contingent consideration component of the Ascyrus acquisition was updated using Level 3 inputs. See Note 3 and Note 4 for further discussion of the Ascyrus acquisition, and the Endospan Loan, respectively. Changes in fair value of Level 3 assets and liabilities are listed in the tables below (in thousands): Endospan Loan Contingent ConsiderationBalance as of December 31, 2020$ 409 $ (59,930)Payments -- 20,000Change in valuation (409) (9,470)Balance as of December 31, 2021$ -- $ (49,400) ‎

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details